Organon (OGN) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $1.513 billion, down 7% as-reported and 4% at constant currency, mainly due to Atozet loss of exclusivity and FX headwinds, but in line with expectations.

• Net income for Q1 2025 was $87 million, a 57% decrease from Q1 2024, with diluted EPS of $0.33 and adjusted diluted EPS of $1.02.

• Adjusted EBITDA was $484 million, representing a 32.0% margin, and adjusted net income was $265 million.

• Key growth drivers included Nexplanon (up 14% ex-FX, on track for over $1 billion in 2025), Follistim AQ, Vtama (targeting $150 million in 2025), and Emgality.

• Significant restructuring and cost-saving initiatives are expected to yield $200 million in annual savings, with a 6% headcount reduction and dividend reset to $0.02 per share to prioritize debt repayment and deleveraging.

Financial highlights

• Revenue declined 7% year-over-year to $1.513 billion; adjusted gross margin was 61.7% (non-GAAP), down from 62.1% in Q1 2024.

• Adjusted EBITDA margin was 32.0%, down from 33.2% in Q1 2024, with free cash flow before one-time costs at $146 million, up from $109 million in Q1 2024.

• Net income margin was 5.8%; adjusted net income margin was 17.5%.

• Cash and cash equivalents stood at $547 million; total debt at $8.96 billion as of March 31, 2025.

• Dividend payout was reset, redirecting nearly $200 million to debt reduction.

Outlook and guidance

• Full-year 2025 revenue guidance remains at $6.125B–$6.325B, with adjusted EBITDA margin guidance of 31.0%–32.0% and adjusted gross margin guidance of 60.0%–61.0%.

• Net leverage ratio targeted below 4.0x by year-end 2025.

• FX headwind of $200 million expected for 2025, but recent dollar weakening could provide upside.

• Vtama is on track to achieve $150 million in revenue for 2025.

• Non-GAAP tax rate for 2025 estimated at 22.5%–24.5%.